CollPlant Biotechnologies (NASDAQ:
CLGN) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.44) by 0.69 percent. This is a 133.87 percent decrease over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $515.000 thousand which missed the analyst consensus estimate of $1.640 million by 68.60 percent.